Gilead to Kick Off Its Own Studies of Potential Coronavirus Drug
February 26 2020 - 5:50PM
Dow Jones News
By Joseph Walker
Gilead Sciences Inc. said Wednesday it would start late-stage
studies of its experimental treatment for the coronavirus in March,
an acceleration of its push to evaluate what it hopes could be the
first medicine specifically approved to treat the respiratory
disease.
Gilead said it will conduct two studies with a total of 1,000
patients across mainly Asian countries, as well as other nations
with high numbers of diagnosed patients.
Gilead is kicking off the studies following the U.S. Food and
Drug Administration's acceptance of its investigational new-drug
application, an early first step for studying unproven drugs in
humans.
The studies, if successful, would help contribute to a larger
dataset needed to win regulatory approval for the drug. It is too
early to say if the two studies alone would be sufficient for
regulators, said Diana Brainard, Gilead senior vice president for
HIV and emerging viral infections.
"Things are moving so quickly, it's hard for us to gauge what
the right approval package would look like in the U.S. or abroad,"
Dr. Brainard said in an interview. "We're in data-collection mode
right now."
Gilead hopes to have at least an initial set of data results in
May, Dr. Brainard said.
Gilead's drug, remdesivir, is already being studied in two sets
of clinical trials. Chinese researchers earlier in February began
enrolling patients with moderate disease and severe disease.
On Tuesday, the National Institutes of Health announced the
start of the first U.S. study of remdesivir, which is being led by
researchers at the University of Nebraska.
(END) Dow Jones Newswires
February 26, 2020 17:35 ET (22:35 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Sep 2023 to Sep 2024